Morbidity of ABO haemolytic disease in the newborn

Y. R. Bhat, C. G. Pavan Kumar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Better understanding of the clinical characteristics of ABO haemolytic disease in neonates helps optimise care. Objective: To assess the morbidity associated with maternal-neonatal ABO incompatibility. Methods: Neonates with blood groups A or B born to mothers with blood group O with simultaneous rhesus blood factor compatibility were studied prospectively. Maternal and neonatal details, direct Coomb's test (DCT) on the cord blood, onset and progression of jaundice, and requirement and duration of phototherapy were studied. Neonates requiring phototherapy were considered to have significant hyperbilirubinaemia, and peripheral smear, reticulocyte count and haematocrit values were obtained. ABO haemolytic disease of the newborn (ABO HDN) is defined as a newborn with a positive DCT and/or laboratory evidence of haemolysis such as reticulocytosis and spherocytes on blood smear. Results: Of 878 deliveries, 151 (17.3%) neonates were ABO incompatible with their mothers. The proportions who were O-A and O-B incompatible were 50.4% and 49.6%, respectively. Forty-six (30.4%) had significant hyperbilirubinaemia (119.7-256.5 mmol/L) and required phototherapy, 26 (34.2%) of them in the O-A group and 20 (26.6%) in the O-B group. None required exchange transfusion. Jaundice was detected within the first 24 hours in 47.8%. Of 46 newborns who required phototherapy, 25 (54.3%) had laboratory evidence of haemolysis. DCT was positive in 1.9% of ABO-incompatible newborns. There was no significant difference in the incidence and severity of haemolysis between the O-A and O-B-incompatible neonates. Neonates with haemolysis required phototherapy significantly earlier and for longer than neonates without haemolysis (P<0.001). Conclusions: ABO incompatibility was observed in 17.3% of pregnancies with almost equal O-A and O-B frequency. About a third of infants had significant hyperbilirubinaemia. There was no difference in severity between those with O-A and O-B HDN.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalPaediatrics and international child health
Volume32
Issue number2
DOIs
Publication statusPublished - 01-05-2012

Fingerprint

Fetal Erythroblastosis
Newborn Infant
Morbidity
Phototherapy
Hemolysis
Coombs Test
Hyperbilirubinemia
Mothers
Blood Group Antigens
Jaundice
Spherocytes
Reticulocytosis
Reticulocyte Count
Fetal Blood
Hematocrit

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{accf8b7772bd40f7bf341d5402dbf13f,
title = "Morbidity of ABO haemolytic disease in the newborn",
abstract = "Background: Better understanding of the clinical characteristics of ABO haemolytic disease in neonates helps optimise care. Objective: To assess the morbidity associated with maternal-neonatal ABO incompatibility. Methods: Neonates with blood groups A or B born to mothers with blood group O with simultaneous rhesus blood factor compatibility were studied prospectively. Maternal and neonatal details, direct Coomb's test (DCT) on the cord blood, onset and progression of jaundice, and requirement and duration of phototherapy were studied. Neonates requiring phototherapy were considered to have significant hyperbilirubinaemia, and peripheral smear, reticulocyte count and haematocrit values were obtained. ABO haemolytic disease of the newborn (ABO HDN) is defined as a newborn with a positive DCT and/or laboratory evidence of haemolysis such as reticulocytosis and spherocytes on blood smear. Results: Of 878 deliveries, 151 (17.3{\%}) neonates were ABO incompatible with their mothers. The proportions who were O-A and O-B incompatible were 50.4{\%} and 49.6{\%}, respectively. Forty-six (30.4{\%}) had significant hyperbilirubinaemia (119.7-256.5 mmol/L) and required phototherapy, 26 (34.2{\%}) of them in the O-A group and 20 (26.6{\%}) in the O-B group. None required exchange transfusion. Jaundice was detected within the first 24 hours in 47.8{\%}. Of 46 newborns who required phototherapy, 25 (54.3{\%}) had laboratory evidence of haemolysis. DCT was positive in 1.9{\%} of ABO-incompatible newborns. There was no significant difference in the incidence and severity of haemolysis between the O-A and O-B-incompatible neonates. Neonates with haemolysis required phototherapy significantly earlier and for longer than neonates without haemolysis (P<0.001). Conclusions: ABO incompatibility was observed in 17.3{\%} of pregnancies with almost equal O-A and O-B frequency. About a third of infants had significant hyperbilirubinaemia. There was no difference in severity between those with O-A and O-B HDN.",
author = "Bhat, {Y. R.} and {Pavan Kumar}, {C. G.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1179/2046905512Y.0000000002",
language = "English",
volume = "32",
pages = "93--96",
journal = "Paediatrics and international child health",
issn = "2046-9047",
publisher = "Maney Publishing",
number = "2",

}

Morbidity of ABO haemolytic disease in the newborn. / Bhat, Y. R.; Pavan Kumar, C. G.

In: Paediatrics and international child health, Vol. 32, No. 2, 01.05.2012, p. 93-96.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Morbidity of ABO haemolytic disease in the newborn

AU - Bhat, Y. R.

AU - Pavan Kumar, C. G.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Background: Better understanding of the clinical characteristics of ABO haemolytic disease in neonates helps optimise care. Objective: To assess the morbidity associated with maternal-neonatal ABO incompatibility. Methods: Neonates with blood groups A or B born to mothers with blood group O with simultaneous rhesus blood factor compatibility were studied prospectively. Maternal and neonatal details, direct Coomb's test (DCT) on the cord blood, onset and progression of jaundice, and requirement and duration of phototherapy were studied. Neonates requiring phototherapy were considered to have significant hyperbilirubinaemia, and peripheral smear, reticulocyte count and haematocrit values were obtained. ABO haemolytic disease of the newborn (ABO HDN) is defined as a newborn with a positive DCT and/or laboratory evidence of haemolysis such as reticulocytosis and spherocytes on blood smear. Results: Of 878 deliveries, 151 (17.3%) neonates were ABO incompatible with their mothers. The proportions who were O-A and O-B incompatible were 50.4% and 49.6%, respectively. Forty-six (30.4%) had significant hyperbilirubinaemia (119.7-256.5 mmol/L) and required phototherapy, 26 (34.2%) of them in the O-A group and 20 (26.6%) in the O-B group. None required exchange transfusion. Jaundice was detected within the first 24 hours in 47.8%. Of 46 newborns who required phototherapy, 25 (54.3%) had laboratory evidence of haemolysis. DCT was positive in 1.9% of ABO-incompatible newborns. There was no significant difference in the incidence and severity of haemolysis between the O-A and O-B-incompatible neonates. Neonates with haemolysis required phototherapy significantly earlier and for longer than neonates without haemolysis (P<0.001). Conclusions: ABO incompatibility was observed in 17.3% of pregnancies with almost equal O-A and O-B frequency. About a third of infants had significant hyperbilirubinaemia. There was no difference in severity between those with O-A and O-B HDN.

AB - Background: Better understanding of the clinical characteristics of ABO haemolytic disease in neonates helps optimise care. Objective: To assess the morbidity associated with maternal-neonatal ABO incompatibility. Methods: Neonates with blood groups A or B born to mothers with blood group O with simultaneous rhesus blood factor compatibility were studied prospectively. Maternal and neonatal details, direct Coomb's test (DCT) on the cord blood, onset and progression of jaundice, and requirement and duration of phototherapy were studied. Neonates requiring phototherapy were considered to have significant hyperbilirubinaemia, and peripheral smear, reticulocyte count and haematocrit values were obtained. ABO haemolytic disease of the newborn (ABO HDN) is defined as a newborn with a positive DCT and/or laboratory evidence of haemolysis such as reticulocytosis and spherocytes on blood smear. Results: Of 878 deliveries, 151 (17.3%) neonates were ABO incompatible with their mothers. The proportions who were O-A and O-B incompatible were 50.4% and 49.6%, respectively. Forty-six (30.4%) had significant hyperbilirubinaemia (119.7-256.5 mmol/L) and required phototherapy, 26 (34.2%) of them in the O-A group and 20 (26.6%) in the O-B group. None required exchange transfusion. Jaundice was detected within the first 24 hours in 47.8%. Of 46 newborns who required phototherapy, 25 (54.3%) had laboratory evidence of haemolysis. DCT was positive in 1.9% of ABO-incompatible newborns. There was no significant difference in the incidence and severity of haemolysis between the O-A and O-B-incompatible neonates. Neonates with haemolysis required phototherapy significantly earlier and for longer than neonates without haemolysis (P<0.001). Conclusions: ABO incompatibility was observed in 17.3% of pregnancies with almost equal O-A and O-B frequency. About a third of infants had significant hyperbilirubinaemia. There was no difference in severity between those with O-A and O-B HDN.

UR - http://www.scopus.com/inward/record.url?scp=84866787678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866787678&partnerID=8YFLogxK

U2 - 10.1179/2046905512Y.0000000002

DO - 10.1179/2046905512Y.0000000002

M3 - Article

VL - 32

SP - 93

EP - 96

JO - Paediatrics and international child health

JF - Paediatrics and international child health

SN - 2046-9047

IS - 2

ER -